EPP alleviates IBD-related pathological injury by inhibiting the JAK2/STAT3 and TRAF6/NF-κB signaling pathways, with its therapeutic mechanism intricately linked to the microbiota-metabolite-host axis. This evidence concerns the gene TRAF6 and inflammatory bowel disease.